ArticleMolecular metabolism2025
Pyruvate kinase deficiency links metabolic perturbations to neurodegeneration and axonal protection.
Article in Molecular metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
objectiveMetabolic disruption is a central feature to many neurodegenerative diseases. Despite this, many gaps exist in our understanding of how these perturbations link to the mechanisms of neural disease. In this study, we sought to understand how genetically-controlled, cell-specific loss of pyruvate kinase (PyK) impacts motor neuron synaptic integrity and how the canonical neurodegenerative proteins DLK and SARM1 respond to this break in homeostasis.
methodsThis study made use of the genetically-tractable Drosophila melanogaster to cell-specifically express proteins (via the GAL4/UAS binary system), knockdown gene transcripts (via RNA interference), and knockout gene loci (via guide RNA-directed Cas9). Synaptic and axonal degeneration were measured through immunohistochemistry, microscopy, and blinded scoring of fly larvae at both early and later 3rd instar stages to test for progressive phenotypes. Nervous system injury through a physical nerve crush assay was used to assay functional outcomes of protective stress responses.
resultsWe found that knockdown or knockout of PyK results in progressive axonal and synaptic degeneration, dependent on signaling through DLK and SARM1. This degeneration is preceded by nuclear transcriptional activation by DLK and the downstream AP-1 transcription factor Fos. We also found evidence of a neuroprotective response through injury of PyK-deficient axons (before progressive degeneration has occurred), which results in delayed Wallerian degeneration. This delay shows dependence on DLK and Fos, and coincides with reduced axonal localization of SARM1 whose overexpression fully restores degeneration speed.
conclusionsThese data support a rheostat model of DLK signaling that both promotes and inhibits axon degeneration in response to metabolic disruption. This rheostat likely converges on regulation of SARM1, which is required for the progressive synapse loss following PyK, but also abolishes the protective delay in injury-induced Wallerian degeneration when overexpressed. Overall, we conclude that metabolic signaling through PyK is essential for the integrity of motor neuron axons and synapses, and that its disruption activates both neurodegenerative and neuroprotective mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.